Eric Kim, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (35.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Intuitive Surgical at 56.2% of the total. Reporting peaked in 2019 at $11,108 and has fallen 94.3% since, to $635 in 2025. Among urology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $272.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$14K
- E.r. Squibb & Sons, L.L.C.$4K
- Histosonics, Inc.$2K
- Janssen Research & Development, LLC$947
- Boston Scientific$655
- Covidien LP$550
- plus $2K from 17 others
Across 1 payment — averaging $123,227 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Histosonics, Inc.$123K
What the payments were for
- Consulting fees$5,79824%
- Speaking & faculty fees$1,7007%
- Travel & lodging$4,58119%
- Food & beverage$3,68315%
- Education$8,50935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 35 | $13,628 |
| E.r. Squibb & Sons, L.L.C. | 8 | $4,353 |
| Histosonics, Inc. | 3 | $2,115 |
| Janssen Research & Development, LLC | 3 | $947 |
| Boston Scientific | 7 | $655 |
| Covidien LP | 1 | $550 |
| BD | 3 | $310 |
| Conmed Corporation | 1 | $300 |
| Angiodynamics, Inc. | 3 | $293 |
| Calyxo, Inc. | 2 | $243 |
| Neotract Inc. | 2 | $134 |
| Janssen Scientific Affairs, LLC | 2 | $125 |
| Baxter Healthcare | 1 | $115 |
| Teleflex LLC | 4 | $98 |
| Innovation Technologies Inc | 1 | $95 |
| Ambu Inc. | 2 | $66 |
| 180 Medical, Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 1 | $47 |
| Johnson & Johnson(2 entities) | 2 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| AbbVie | 2 | $31 |
| Convatec Inc. | 1 | $25 |
| Merck | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$11,524
- DA VINCI SP$1,500
- Sonicision$550
- Bard Urinary Drainage Bag$284
- Nanoknife$227
- CVAC Aspiration System$189
- SpaceOAR VUE System - 10mL$157
- LithoVue$148
- PerClot$115
- UroLift$110
- Balversa$109
- AMS$102
How this compares
$24,270 in reported general payments places this provider in the 90th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 46 | $26,494 |
| Tamsulosin Hcl | 316 | $3,545 |
| Finasteride | 321 | $3,122 |
| Estradiol | 12 | $882 |
| Silodosin | 16 | $532 |
| Oxybutynin Chloride ErOxybutynin Chloride | 39 | $492 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $439 |
| Oxybutynin Chloride | 17 | $345 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $248 |
| Ciprofloxacin Hcl | 49 | $226 |
| Levofloxacin | 11 | $64 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $34 | $26,49446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 63 urology providers in Nevada.
Other urology in Reno
- Christopher EvansReno$184K
- Nicholas HauserReno$12K
- Angelo KanellosReno$11K
- Timothy SuttleReno$8K
- Ross AndersonReno$7K
- Matthew McCormackReno$3K
- Chloe ShenkReno$3K
- Christopher TamReno$3K
- Dielle DuvalReno$3K
- Remy LambertsReno$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.